Skip to the content
ClearNote Health logologo darklogo light
  • Our Story
    • About Us
    • Leadership Team
    • FAQs
    • Careers
  • Our Approach
    • Epigenomics Platform
    • Clinical Trials
    • Publications
  • Our Products
    • Biopharma
    • Pancreatic Cancer
    • Ovarian Cancer
  • Our News
  • Contact Us
  • Order Test
Search
ClearNote Health logo
  • Our Story
    • About Us
    • Leadership Team
    • FAQs
    • Careers
  • Our Approach
    • Epigenomics Platform
    • Clinical Trials
    • Publications
  • Our Products
    • Biopharma
    • Pancreatic Cancer
    • Ovarian Cancer
  • Our News
  • Contact Us
  • Order Test
ClearNote Health logo
  • Our Story
    • About Us
    • Leadership Team
    • FAQs
    • Careers
  • Our Approach
    • Epigenomics Platform
    • Clinical Trials
    • Publications
  • Our Products
    • Biopharma
    • Pancreatic Cancer
    • Ovarian Cancer
  • Our News
  • Contact Us
  • Order Test
Home2023June
Event

ClearNote Health is Attending the American Diabetes Association’s 83rd Scientific Sessions in San Diego, June 23-26

cnhnewcorpdev
June 8, 2023
Event

American Diabetes Association 83rd Scientific Sessions | June, 2023

cnhnewcorpdev
June 1, 2023

ClearNote Health to Present Industry-Leading Early Detection Data for Avantect® Pancreatic Cancer Test at Digestive Disease Week 2026

ClearNote Health
May 8, 2026

ClearNote Health to Showcase Industry-Leading Early Detection Performance of the Avantect® Pancreatic Cancer Test at AACR Annual Meeting 2026

cnhnewcorpdev
April 15, 2026

Follow us
ClearNote Health logo
Empowering early cancer detection through DNA-based blood tests and our proprietary epigenomics platform.
Order Test
Company
  • About Us
  • Leadership Team
  • Our News
  • Careers
  • Contact Us
Products
  • Avantect Pancreatic Cancer Test
  • Avantect Ovarian Cancer Test
  • Avantect MCD Test
  • Virtuoso Epigenomics Platform
Stay Informed

Get the latest research and announcements from ClearNote Health.

Important information: The Virtuoso platform is for research use only. Not for use in diagnostic procedures.

The Avantect Pancreatic and Ovarian Cancers Tests are early detection tests. The tests do not establish a diagnosis of pancreatic cancer or ovarian cancer, respectively, and results should be considered in the context of other clinical criteria.

Cancer statistics quoted on this website are taken from the CDC and SEER websites, 2025 data.

©2026 ClearNote Health, All Rights Reserved.

Avantect and Virtuoso are trademarks of ClearNote Health. Other trademarks are the property of their respective owners.

  • Privacy Policy
  • Terms of Use
  • Billing rights & protections
  • Cookie Preferences